YOU were the one expressing your disdain for CONgress. I have similar views, and I suspect that Shkreli does, as well.
Maybe bio-pharms, in development stage and relying on equity financing, wouldn't have such high R&D expenses, if the price of their shares wasn't criminally decimated. So if the Oversight Committee wants to cut health care costs, they can at least make sure that companies that are in the health care industry are treated lawfully in the equity market.
News 
Market Data 
Discover 
